clinical trial · NCT07222332
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Eli Lilly and Company·phase3·recruiting·n = 300
Diabetes Mellitus, Type 1BaricitinibPlacebo
brief summary
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
started
Feb 5, 2026
primary completion
Jul 1, 2028
completion
Jul 1, 2028
last updated
Jun 4, 2026
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol